Profile Your Partner Often it’s beneficial to get the partner to sell you on why they would make a good partner. Ask them for a capabilities presentation. Ask them how they’re going to maximize the value of your asset. Understand their pipeline and how your asset will fit into it. For example, if you have an asset that has multiple indications, it’s very important to have a discussion about how they’re going to develop multiple indications. Do they see the priority the same way you do?
Great weekend re-read: c.ymcdn.com/sites/www.bioflorida.com/resource/resmgr/imported/ShareVault%20whitepaper%20-%20Getting%20Ready%20for%20BioPharma%20Partnering%20v2.pdf
Remember Leo confirmed they have had a great virtual room with cable!
“A typical large pharmaceutical might see 500 to 1,000 opportunities in a given therapeutic area. Only 100 or so of those will go on to non-con dential meetings and only 50 or so of those will end up going to Con dential Disclosure Agreements (CDAs) and con dential meetings.”